These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28742419)

  • 1. Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.
    Gomez-de-León A; Gómez-Almaguer D; Ruiz-Delgado GJ; Ruiz-Arguelles GJ
    Expert Rev Hematol; 2017 Sep; 10(9):809-819. PubMed ID: 28742419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia.
    Mathisen MS; Kantarjian HM; Cortes J; Jabbour EJ
    Blood Rev; 2014 Sep; 28(5):179-87. PubMed ID: 24984571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to Consider Allogeneic Transplantation in CML.
    Radich J
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era.
    Pasquini MC
    Hematology; 2012 Apr; 17 Suppl 1():S79-82. PubMed ID: 22507787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
    Rochau U; Sroczynski G; Wolf D; Schmidt S; Conrads-Frank A; Jahn B; Saverno K; Brixner D; Radich J; Gastl G; Siebert U
    Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Gratwohl A; Baldomero H; Passweg J
    Ann Hematol; 2015 Apr; 94 Suppl 2():S177-86. PubMed ID: 25814084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: targeting both therapeutic modalities.
    Fernandez HF; Kharfan-Dabaja MA
    Cancer Control; 2009 Apr; 16(2):153-7. PubMed ID: 19337201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
    Rea D; Mahon FX
    Br J Haematol; 2018 Jan; 180(1):24-32. PubMed ID: 29048128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
    Innes AJ; Apperley JF
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
    Zhao Y; Wang J; Luo Y; Shi J; Zheng W; Tan Y; Cai Z; Huang H
    Ann Hematol; 2017 Aug; 96(8):1353-1360. PubMed ID: 28624905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
    Nair AP; Barnett MJ; Broady RC; Hogge DE; Song KW; Toze CL; Nantel SH; Power MM; Sutherland HJ; Nevill TJ; Abou Mourad Y; Narayanan S; Gerrie AS; Forrest DL
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1437-44. PubMed ID: 25865648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia.
    Kavanagh S; Nee A; Lipton JH
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):51-62. PubMed ID: 29480034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of allogeneic transplantation in chronic myeloid leukemia.
    Heim D; Gratwohl A
    Expert Rev Hematol; 2008 Oct; 1(1):41-50. PubMed ID: 21083006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The choice of first-line chronic myelogenous leukemia treatment.
    Fava C; Rege-Cambrin G; Saglio G
    Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.